Linked Life Data

12755551

Source:http://linkedlifedata.com/resource/pubmed/id/12755551

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2003-5-20
pubmed:abstractText
Rofecoxib and celecoxib (coxibs) effectively treat chronic arthritis pain and reduce ulcer complications by 50% compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs). However, their absolute risk reduction is small and the cost-effectiveness of treatment is uncertain.
pubmed:grant
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents..., http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2 Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Isoenzymes, http://linkedlifedata.com/resource/pubmed/chemical/Lactones, http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins, http://linkedlifedata.com/resource/pubmed/chemical/PTGS2 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Prostaglandin-Endoperoxide Synthases, http://linkedlifedata.com/resource/pubmed/chemical/Pyrazoles, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides, http://linkedlifedata.com/resource/pubmed/chemical/Sulfones, http://linkedlifedata.com/resource/pubmed/chemical/celecoxib, http://linkedlifedata.com/resource/pubmed/chemical/rofecoxib
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1539-3704
pubmed:author
pubmed:issnType
Electronic
pubmed:day
20
pubmed:volume
138
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
795-806
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:12755551-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:12755551-Arthritis, Rheumatoid, pubmed-meshheading:12755551-Cardiovascular Diseases, pubmed-meshheading:12755551-Chronic Disease, pubmed-meshheading:12755551-Cost-Benefit Analysis, pubmed-meshheading:12755551-Cyclooxygenase 2, pubmed-meshheading:12755551-Cyclooxygenase 2 Inhibitors, pubmed-meshheading:12755551-Cyclooxygenase Inhibitors, pubmed-meshheading:12755551-Decision Support Techniques, pubmed-meshheading:12755551-Humans, pubmed-meshheading:12755551-Isoenzymes, pubmed-meshheading:12755551-Lactones, pubmed-meshheading:12755551-Membrane Proteins, pubmed-meshheading:12755551-Osteoarthritis, pubmed-meshheading:12755551-Peptic Ulcer, pubmed-meshheading:12755551-Prostaglandin-Endoperoxide Synthases, pubmed-meshheading:12755551-Pyrazoles, pubmed-meshheading:12755551-Quality-Adjusted Life Years, pubmed-meshheading:12755551-Recurrence, pubmed-meshheading:12755551-Risk Factors, pubmed-meshheading:12755551-Sensitivity and Specificity, pubmed-meshheading:12755551-Sulfonamides, pubmed-meshheading:12755551-Sulfones
pubmed:year
2003
pubmed:articleTitle
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
pubmed:affiliation
Veterans Administration Greater Los Angeles Healthcare System, David Geffen School of Medicine at University of California, CURE Digestive Diseases Research Center, Los Angeles, CA 90073, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Review, Meta-Analysis